Yahoo · Sep 22, 2026
Is Centene (CNC) Stock Outpacing Its Medical Peers This Year?
Here is how Centene (CNC) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.
AL
NASDAQ · ALZN
Alzamend Neuro, Inc.
Healthcare · Biotechnology
$1.37
Down-$0.03 (-2.19%)
Updated Oct 9, 2026, 1:17 AM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 6.31M
- P/E ratio
- -1.16
- Dividend yield
- 0.00%
- 52-week range
- $0.84 – $2.36
- Volume
- 18.89K
- Avg. volume
- 73.67K
Price performance · ALZN
ALZN price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
ALZN closed at $1.37 after 20 trading sessions, down 19.41% for the selected period.
- Last close
- $1.37
- Period change
- -19.41%
- Period low
- $1.32
- Period high
- $1.94
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $1.37 | $1.42 | $1.34 | $1.37 | 18.89K |
| Oct 6, 2026 | $1.4352 | $1.4352 | $1.3428 | $1.37 | 32.05K |
| Oct 5, 2026 | $1.38 | $1.48 | $1.375 | $1.41 | 25.42K |
| Oct 2, 2026 | $1.41 | $1.48 | $1.20 | $1.37 | 236.38K |
| Oct 1, 2026 | $1.72 | $1.72 | $1.26 | $1.315 | 150.75K |
| Sep 30, 2026 | $1.84 | $1.84 | $1.73 | $1.73 | 21.69K |
| Sep 29, 2026 | $1.7452 | $1.85 | $1.7399 | $1.82 | 49.61K |
| Sep 28, 2026 | $1.80 | $1.9199 | $1.73 | $1.73 | 83.83K |
| Sep 25, 2026 | $1.90 | $1.90 | $1.7635 | $1.83 | 23.32K |
| Sep 24, 2026 | $1.90 | $1.93 | $1.82 | $1.82 | 150.56K |
| Sep 23, 2026 | $1.93 | $1.95 | $1.93 | $1.94 | 45.87K |
| Sep 22, 2026 | $1.93 | $1.94 | $1.90 | $1.94 | 91.22K |
| Sep 21, 2026 | $1.89 | $1.94 | $1.87 | $1.94 | 206.81K |
| Sep 18, 2026 | $1.84 | $1.89 | $1.8101 | $1.89 | 241.87K |
| Sep 17, 2026 | $1.83 | $1.84 | $1.82 | $1.84 | 42.65K |
| Sep 16, 2026 | $1.79 | $1.85 | $1.79 | $1.83 | 168.84K |
| Sep 15, 2026 | $1.75 | $1.79 | $1.725 | $1.78 | 230.62K |
| Sep 14, 2026 | $1.72 | $1.76 | $1.7085 | $1.75 | 69.17K |
| Sep 11, 2026 | $1.67 | $1.76 | $1.59 | $1.72 | 393.65K |
| Sep 10, 2026 | $1.67 | $1.70 | $1.5757 | $1.70 | 9.49K |
Latest ALZN news
The latest Smart Investors Daily articles mentioning ALZN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ALZN research
Overview
Company profile and research snapshot.
Company profile
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $42.84
- Implied upside
- —
- Analysts
- 8
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 19, 2026 | Ascendiant Capital | Buy | — |
| Dec 22, 2025 | Ascendiant Capital | Buy | — |
| Sep 25, 2025 | Ascendiant Capital | Buy | — |
| Aug 21, 2025 | Ascendiant Capital | Buy | — |
| Mar 17, 2025 | Ascendiant Capital | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 16, 2026
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it has received a notification letter (the "Compliance Notice") from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC ("Nasdaq") dated September 14, 2026, informing Alzame
Benzinga · Sep 16, 2026
Alzamend Neuro Regains Nasdaq Compliance
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar
Benzinga · Sep 10, 2026
Alzamend Neuro Q1 EPS $(0.68) Misses $(0.56) Estimate, Sales $0.00, Same YoY
Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.56) by 21.43 percent. This is a 46.88 percent increase over losses of $(1.28) per share from
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
